Cargando…

Biomarker MET in der Tumorpathologie

Detalles Bibliográficos
Autores principales:	Ihle, Michaela Angelika, Heydt, Carina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Medizin 2023
Materias:	Molekulares Tumorboard
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160147/ https://www.ncbi.nlm.nih.gov/pubmed/36944766 http://dx.doi.org/10.1007/s00292-023-01189-2

Ejemplares similares

Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
por: Stenzinger, Albrecht, et al.
Publicado: (2020)

Angiotensinkonvertierendes Enzym 2 (ACE2): Rolle in der Pathogenese von Erkrankungen außerhalb von COVID-19
por: Mülling, N., et al.
Publicado: (2021)

Overview of Molecular Detection Technologies for MET in Lung Cancer
por: Heydt, Carina, et al.
Publicado: (2023)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Molekulare Pinzetten als Breitbandinhibitor viraler Infektionen
por: Weil, Tatjana, et al.
Publicado: (2023)

30 Jahre Nanobodies: Neues von kleinen Helfern mit großem Potenzial
por: Wagner, Teresa R., et al.
Publicado: (2023)

Strukturierte RNAs in Viren
por: Ochsenreiter, Roman, et al.
Publicado: (2023)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics
por: Heydt, Carina, et al.
Publicado: (2014)

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy
por: Heydt, Carina, et al.
Publicado: (2015)

Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
por: Gamerith, Gabriele, et al.
Publicado: (2022)

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
por: Heydt, Carina, et al.
Publicado: (2019)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
por: Castiglione, Roberta, et al.
Publicado: (2018)

Biomarker development in MET-targeted therapy
por: Zhang, Yanni, et al.
Publicado: (2016)

HGF-MET as a breast cancer biomarker
por: Liu, Shuying
Publicado: (2015)

Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity
por: Bersani, Francesca, et al.
Publicado: (2023)

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC
por: Jie, Guang-Ling, et al.
Publicado: (2023)

Der FOKO ist zurück!
por: Bauer-Delto, Angelika
Publicado: (2021)

Innovative Therapieoptionen in der Dermatologie
por: Bauer-Delto, Angelika
Publicado: (2022)

KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm?
por: Wittersheim, Maike, et al.
Publicado: (2017)

Neues aus der ästhetischen Dermatologie
por: Bauer-Delto, Angelika
Publicado: (2020)

Placeboeffekte in der Schmerztherapie: Einfluss der Erwartung auf die Wirksamkeit und Verträglichkeit schmerzmedizinischer Behandlungen
por: Kunkel, Angelika, et al.
Publicado: (2023)

Logistik in der Krise
por: Endemann, Michaela
Publicado: (2021)

Hepatocyte growth factor/MET in cancer progression and biomarker discovery
por: Matsumoto, Kunio, et al.
Publicado: (2017)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

… damit sie uns nicht verloren gehen!: Der Sport und die Kinderrechte während der Pandemie
por: Faulhaber, Alexandra, et al.
Publicado: (2021)

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer
por: Piguet, Anne-Christine, et al.
Publicado: (2015)

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
por: Nisa, Lluís, et al.
Publicado: (2017)

COVID-19 - auch in der Dermatologie allgegenwärtig
por: Bauer-Delto, Angelika
Publicado: (2022)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
por: Shuch, Brian, et al.
Publicado: (2015)

Bedarfe der Langzeitpflege in der COVID-19-Pandemie
por: Stolle, Claudia, et al.
Publicado: (2020)

Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022)

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
por: Kim, Jooseok, et al.
Publicado: (2020)

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
por: Alidousty, Christina, et al.
Publicado: (2018)

Neurobiologische und neurochemische Mechanismen der Placeboanalgesie
por: Asan, Livia, et al.
Publicado: (2022)

HGF/c-Met related activation of β-catenin in hepatoblastoma
por: Purcell, Rachel, et al.
Publicado: (2011)

Langzeitfolgen von COVID-19 - auch in der HNO-Praxis
por: Bauer-Delto, Angelika
Publicado: (2021)

Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qb16bg2gluk2v90p2lh0t5b205